History of urological malignancies before kidney transplantation, oncological outcome on the long term
| Autor: | José Daniel Subiela, Luis Guirado, Angelo Territo, A. Gallioli, A. Sánchez-Puy, C. Martinez, Jorge Huguet, Asier Mercadé, D. Vanacore, R. Hidalgo, Alberto Breda, Juan Palou, R. Boissier, O. Rodríguez Faba |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Oncology
Male medicine.medical_specialty Urologic Neoplasms medicine.medical_treatment Urology Outcome (game theory) Upper Urinary tract urothelial carcinoma Metastasis Kidney transplantation Prostate cancer Testicular cancer Renal cell carcinoma Internal medicine medicine Humans Intensive care medicine Dialysis Cancer staging Retrospective Studies Bladder cancer business.industry Cancer General Medicine medicine.disease Kidney Transplantation Term (time) Kidney Failure Chronic Neoplasm Recurrence Local business Non-muscle invasive bladder cancer |
| Zdroj: | Actas Urologicas Espanolas r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau instname |
| ISSN: | 2173-5786 0210-4806 |
| Popis: | Introduction: We aimed to report the oncological outcomes of ESRD patients with histories of urological malignancies who were subsequently submitted to kidney transplantation (KT). Material and method: Retrospective study lead in the Puigvert Foundation (Barcelona) registry of 1,200 KT performed from 1988 to 2018. Eighty-five urological malignancies that were treated before KT in 81 patients were identified: 15 (18%) prostate cancers, 49 (58%) RCC, 19 (22%) urothelial carcinomas and 2 (2%) testicular cancers. Baseline characteristics, cancer staging, treatment and follow-up were registered as well as the chronology of the start of dialysis, inscription on the waiting list and kidney transplantation. Endpoints included were cancer recurrence, metastatic progression, cancer-specific death and overall survival. Results: In a median follow-up of 13.1 years (2.2-32), 16/85 (19%) cancer recurrences were reported, with 3 (4%) who progressed to metastasis and died of cancer. Median overall survival after cancer treatment was 25.3 years and cancer-specific survival was 95% at 25 years. Median time from cancer treatment to kidney transplantation was 4.8 years: 3.7 years in prostate cancer, 3.9 years in RCC and 8.8 years in bladder cancer. The median time from start of dialysis to kidney transplantation was 1.8 years in patients with histories of urological malignancy versus 0.5 year in the total cohort of 1,200 renal transplanted over the same period Conclusions: Well-selected patients with histories of urological malignancies greatly benefit from kidney transplantation with infrequent and late cancer recurrence. Waiting time could be optimized in low-risk prostate cancer and RCC, but more robust data are needed. (C) 2021 AEU. Published by Elsevier Espana, S.L.U. All rights reserved. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect